AI Article Synopsis
Article Abstract
Objectives: The combination of irinotecan and raltitrexed is safe and active in 5-fluorouracil-refractory, metastatic colorectal cancer (CRC), with the advantage of its convenient three-weekly schedule. The aim of this multicenter phase II study was to assess its efficacy and toxicity in first-line treatment.
Methods: Between May 2000 and March 2001, 62 previously untreated patients received irinotecan (350 mg/m(2)) plus raltitrexed (3 mg/m(2)), with courses repeated every 21 days. Objective response was assessed every three courses, and treatment maintained until tumor progression or unacceptable toxicity.
Results: A total of 331 cycles were administered, with a median of five cycles per patient (range, 1-16). Seventeen patients achieved a partial response and 2 a complete response, for an overall intention-to-treat response rate of 30% (95% confidence interval, 18-44%). The incidence of grade 3-4 toxicity per patient was diarrhea (27%), emesis (13%), anemia (12%), neutropenia (9%), and asthenia (7%). Three patients (5%) died from treatment-related adverse events (diarrhea plus neutropenia). The median potential follow-up is now 37 months. Median survival was 12.2 months, and median time to progression was 6.3 months.
Conclusions: The combination of irinotecan plus raltitrexed is an easy comfortable schedule for patients with metastatic CRC, but both efficacy and toxicity results seem suboptimal for first-line treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000084821 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial.
Cancer Control
September 2024
Medical Oncology Department, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Objectives: Clinical studies have shown that bevacizumab plus chemotherapy significantly improves efficacy in metastatic colorectal cancer (mCRC). This prospective study aims to investigate the efficacy and safety of changing second-line treatment to raltitrexed-based chemotherapy regimens plus bevacizumab in mCRC patients who have failed the first-line fluorouracil-based chemotherapy regimen with or without bevacizumab/cetuximab.
Methods: This is a prospective, open-label, multicenter, phase II clinical study.
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study.
BMC Cancer
September 2024
Department of Oncology, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Background: Colorectal cancer is the third most common cancer and the second leading cause of cancer death. There are limited therapeutic options for the treatment of locally advanced or metastatic colorectal cancers which fail first-line chemotherapy. Phase I/II studies showed that the combined application of the raltitrexed and irinotecan has significant synergistic effect and acceptable toxicity.
View Article and Find Full Text PDFIrinotecan plus raltitrexed as second‑line chemotherapy for metastatic colorectal cancer: A retrospective study.
Oncol Lett
September 2024
Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China.
The present study evaluated the efficiency, prognostic factors for and the safety of irinotecan combined with raltitrexed (TOMIRI) in patients with metastatic colorectal cancer (CRC). Outcome data of patients who received TOMIRI as first-, second- and third- or later-line treatment regimens were assessed to compare the efficacy of this regimen. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) were evaluated for each group.
View Article and Find Full Text PDFSALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.
Cancer Commun (Lond)
August 2024
Department of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China.
Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study.
J Gastrointest Oncol
April 2024
Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of gemcitabine combined with raltitrexed or S-1 as third-line treatments for metastatic colorectal cancer (mCRC), in contrast to standard third-line therapies like TAS-102 and regorafenib, which have shown subpar efficacy and notable side effects.
- A total of 60 patients who had already undergone at least two lines of prior treatments were included, with progression-free survival (PFS) and overall survival (OS) tracked to compare treatment outcomes.
- Results showed that while there were no significant differences in median OS or PFS among the treatment groups, the overall response and disease control rates varied,
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!